Evaluation of Molecular Biomarkers and Response to Therapy in Prostate Cancer

Prostate cancer is the most common cancer in men. Prostate cancer has a long natural history, and development of metastatic disease may not be detected for approximately 5 years after initial diagnosis. The backbone of therapy for patients with metastatic disease is androgen deprivation therapy (ADT). For patients whose disease has progressed despite ADT, there are many additional treatment options. However, optimal treatment choice and sequencing are unknown. Genetic variations are being increasingly recognized in prostate cancer. These variations may evolve throughout the natural history of the disease, and may affect disease progression and response to different therapies. Most patients who had mutations in AR, PI3K, and DNA repair genes had a lower time to PSA progression compared to the historical cohort